These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 25053453)

  • 1. Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
    Patel DA; Shorr AF; Chastre J; Niederman M; Simor A; Stephens JM; Charbonneau C; Gao X; Nathwani D
    Crit Care; 2014 Jul; 18(4):R157. PubMed ID: 25053453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany.
    De Cock E; Krueger WA; Sorensen S; Baker T; Hardewig J; Duttagupta S; Müller E; Piecyk A; Reisinger E; Resch A
    Infection; 2009 Apr; 37(2):123-32. PubMed ID: 19277465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health economic evaluation of patients treated for nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus: secondary analysis of a multicenter randomized clinical trial of vancomycin and linezolid.
    Niederman MS; Chastre J; Solem CT; Wan Y; Gao X; Myers DE; Haider S; Li JZ; Stephens JM
    Clin Ther; 2014 Sep; 36(9):1233-1243.e1. PubMed ID: 25066668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linezolid Versus Vancomycin in the Empiric Treatment of Nosocomial Pneumonia: A Cost-Utility Analysis Incorporating Results from the ZEPHyR Trial.
    Collins CD; Schwemm AK
    Value Health; 2015 Jul; 18(5):614-21. PubMed ID: 26297089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacotherapy for methicillin-resistant Staphylococcus aureus nosocomial pneumonia.
    Segarra-Newnham M; Church TJ
    Ann Pharmacother; 2012 Dec; 46(12):1678-87. PubMed ID: 23232021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
    Estes L; Orenstein R
    Clin Ther; 2007 Feb; 29(2):381-3; author reply 383-4. PubMed ID: 17472831
    [No Abstract]   [Full Text] [Related]  

  • 7. Nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus treated with linezolid or vancomycin: A secondary economic analysis of resource use from a Spanish perspective.
    Rello J; Nieto M; Solé-Violán J; Wan Y; Gao X; Solem CT; De Salas-Cansado M; Mesa F; Charbonneau C; Chastre J
    Med Intensiva; 2016 Nov; 40(8):474-482. PubMed ID: 27061776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of linezolid versus vancomycin in mechanical ventilation-associated nosocomial pneumonia caused by methicillin-resistant staphylococcus aureus.
    Machado AR; Arns Cda C; Follador W; Guerra A
    Braz J Infect Dis; 2005 Jun; 9(3):191-200. PubMed ID: 16224625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
    Lyles A
    Clin Ther; 2007 Feb; 29(2):384. PubMed ID: 17472833
    [No Abstract]   [Full Text] [Related]  

  • 10. An economic model to compare linezolid and vancomycin for the treatment of confirmed methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany.
    Patel DA; Michel A; Stephens J; Weber B; Petrik C; Charbonneau C
    Infect Drug Resist; 2014; 7():273-80. PubMed ID: 25368526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis.
    Bounthavong M; Zargarzadeh A; Hsu DI; Vanness DJ
    Value Health; 2011; 14(5):631-9. PubMed ID: 21839399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation among Chinese patients with nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus and treated with linezolid or vancomycin: a secondary, post-hoc analysis based on a Phase 4 clinical trial study.
    Wan Y; Li Q; Chen Y; Haider S; Liu S; Gao X
    J Med Econ; 2016; 19(1):53-62. PubMed ID: 26490296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
    McKinnon PS; Sorensen SV; Liu LZ; Itani KM
    Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
    Daniel Mullins C; Kuznik A; Shaya FT; Obeidat NA; Levine AR; Liu LZ; Wong W
    Clin Ther; 2006 Aug; 28(8):1184-1198. PubMed ID: 16982296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study.
    Wunderink RG; Niederman MS; Kollef MH; Shorr AF; Kunkel MJ; Baruch A; McGee WT; Reisman A; Chastre J
    Clin Infect Dis; 2012 Mar; 54(5):621-9. PubMed ID: 22247123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating the cost-effectiveness of linezolid for the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Taiwan.
    Lin PC; Wang BC; Kim R; Magyar A; Lai CC; Yang YW; Huang YC
    J Microbiol Immunol Infect; 2016 Feb; 49(1):46-51. PubMed ID: 26454421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of weight on treatment efficacy and safety in complicated skin and skin structure infections and nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
    Puzniak LA; Morrow LE; Huang DB; Barreto JN
    Clin Ther; 2013 Oct; 35(10):1557-70. PubMed ID: 24011955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
    Estes L; Orenstem R
    Clin Ther; 2007 Apr; 29(4):759-60; author reply 760-1. PubMed ID: 17617300
    [No Abstract]   [Full Text] [Related]  

  • 19. Economic evaluation of linezolid, flucloxacillin and vancomycin in the empirical treatment of cellulitis in UK hospitals: a decision analytical model.
    Vinken A; Li Z; Balan D; Rittenhouse B; Wilike R; Nathwani D
    J Hosp Infect; 2001 Dec; 49 Suppl A():S13-24. PubMed ID: 11926436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patients.
    McCollum M; Sorensen SV; Liu LZ
    Clin Ther; 2007 Mar; 29(3):469-77. PubMed ID: 17577468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.